Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124241 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00124241: Completed Phase 2 study, sponsored by Novartis.
NCT00124241 is a Phase 2 study that has completed, run by Novartis. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00124241, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This is an extension study for patients who have previously completed Idenix Study NV-02B-003. This study is being conducted to compare the safety and effectiveness of treatment beyond 1 year of telbivudine and telbivudine combined with lamivudine, a drug currently approved for the treatment of hepatitis B.
Interventions
- DRUG lamivudine
- DRUG telbivudine
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00124241 record still lists
NCT00124241 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which lamivudine is the first listed.
NCT00124241 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00124241 about?
NCT00124241 is a clinical study titled "An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B". This is an extension study for patients who have previously completed Idenix Study NV-02B-003. This study is being conducted to compare the safety and effectiveness of treatment beyond 1 year of telbivudine and telbivudine combined with lamivudine, a drug currently approved for the treatment of hepa...
What is the current status of trial NCT00124241?
This trial is currently completed. It is a Phase 2 study. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00124241?
The interventions under investigation include: lamivudine (DRUG), telbivudine (DRUG).
Who is sponsoring clinical trial NCT00124241?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.